Abstract
We performed bacteriological and clinical studies on pazufloxacin (PZFX), a new quinolone derivative, in respiratory tract infections and obtained the following results.
1) The MIC90 of PZFX against Staphylococcus aureus, Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae and Pseudomonas aeruginosa were 0.03-4μg/ml, which were almost equal to those of sparfloxacin (SPFX) and levofloxacin (LVFX). The MIC against methicilline resistant S. aureus and Streptococcus pneumoniae were inferior to those of SPFX and LVFX.
2) Ten patients with respiratory tract infections were treated with PZFX. The effect of the agents on the infections was good in nine, unevaluable in one.
No adverse reaction was obtained in any of the patients.
Abnormal laboratory findings were observed in 2 patients with mild liver damage.
